Communiqués Myriad Genetics, Inc.

Actions

MYGN

US62855J1043

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 20:44:33 25/09/2026			Varia. 5j.	Varia. 1 janv.
4,215 ^USD	+1,81 %		+7,84 %	-31,79 %

16/09	Myriad Genetics, Inc. annonce des changements au sein de sa direction	CI
09/09	Myriad Genetics, Inc. : UBS est neutre sur le titre	ZM

Communiqués

16/09	Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial	GL
16/09	Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial	AQ
27/08	Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference	GL
30/07	Myriad: Q2 Earnings Snapshot	AQ
30/07	Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability	GL
23/07	Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026	GL
21/07	Myriad Genetics Launches FirstGene® Multiple Prenatal Screen	GL
02/07	New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer	GL
23/06	Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication	GL
02/06	Myriad Genetics Names Raj Jampa as New Chief Technology Officer	GL
27/05	Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting	GL
26/05	Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)	GL
15/05	Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life	GL
08/05	Myriad Genetics : to Participate in Upcoming Investor Healthcare Conferences	PU
07/05	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences	GL
05/05	Myriad: Q1 Earnings Snapshot	AQ
05/05	Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business	GL
01/05	Myriad Genetics National Survey, 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan	AQ
30/04	Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan	GL
28/04	Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026	GL
16/04	Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026	GL
14/04	Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan	GL
14/04	Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan	AQ
09/04	Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting	GL
17/03	Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer	GL